SciSparc Acquires MUSE™ Endoscopy Patents to Target $3 Billion GERD Device Market
Key Insights
SciSparc Ltd. signed a binding term sheet to acquire patents for the MUSE™ endoscopic system from Xylo Technologies, targeting gastroesophageal reflux disease (search) treatment.
The MUSE™ system is a single-use endoscopic device designed for transoral fundoplication, a minimally invasive procedure to treat GERD (search).
SciSparc plans to replicate Xylo's successful Greater China commercialization model across North America, Europe, and Latin America through exclusive partnerships.
SciSparc Ltd. (Nasdaq: SPRC) announced on November 26, 2025, the signing of a binding term sheet to acquire a comprehensive portfolio of patents, trademarks, and intellectual property rights for innovative endoscopic systems and medical cameras from Xylo Technologies Ltd. (search) The acquisition centers on the MUSE™ system, a single-use endoscopic device designed for transoral fundoplication, a minimally invasive procedure to treat gastroesophageal reflux disease (search) (GERD (search)).
Strategic Market Expansion
The acquisition builds on Xylo's proven commercialization success in Greater China, where the company secured a licensing and distribution agreement with a Shanghai-based medical instruments company in 2019, receiving $3 million upfront. SciSparc aims to replicate this model across high-growth territories including North America, Europe, and Latin America by pursuing exclusive partnerships with leading regional distributors.
The strategic move positions SciSparc to capitalize on the expanding GERD (search) device market. According to a May 2025 market research report by MarkNtel Advisors, the global GERD device market was valued at approximately $2.5 billion in 2024 and is projected to reach $3.03 billion by 2030, representing a compound annual growth rate (CAGR) of 3.24% from 2025 to 2030.
Transaction Structure
Under the binding term sheet terms, SciSparc will acquire the complete portfolio of patents, trademarks, know-how, and related intellectual property rights primarily associated with the MUSE™ system. In consideration for these assets, SciSparc will issue ordinary shares representing 19.99% of the company's issued and outstanding share capital as of the closing date. The company retains the discretion to issue pre-funded warrants to purchase ordinary shares in lieu of some or all of the issued shares.
The transaction remains subject to negotiating and signing definitive agreements between SciSparc and Xylo Technologies.
Company Background
SciSparc operates through its majority-owned subsidiary NeuroThera Labs Inc. (search), focusing on clinical-stage pharmaceutical developments. The company's primary focus involves creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. Current drug development programs include SCI-110 for treating Tourette syndrome (search), Alzheimer's disease (search) and agitation, and SCI-210 for treating ASD (search) and status epilepticus (search), all based on THC and/or non-psychoactive CBD compounds.